These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6228033)

  • 1. Comparative study of thrombolysis by high and low molecular weight urokinase in an in vitro perfusion system.
    Greenwald SR; Chandler AB
    Thromb Res; 1983 Sep; 31(6):799-806. PubMed ID: 6228033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of urokinase-induced thrombolysis in a biphasic in vitro system.
    Iga Y; Stella SR; Chandler AB
    Haemostasis; 1985; 15(3):189-97. PubMed ID: 4029755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
    Korninger C; Matsuo O; Suy R; Stassen JM; Collen D
    J Clin Invest; 1982 Mar; 69(3):573-80. PubMed ID: 7199539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture.
    Rijken DC; Binnema DJ; Los P
    Thromb Res; 1986 Jun; 42(6):761-8. PubMed ID: 2425448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
    Terres W; Beythien C; Kupper W; Bleifeld W
    Circulation; 1989 Jun; 79(6):1309-14. PubMed ID: 2720929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogenolysis and fibrinolysis in normal volunteers and patients with thrombosis after infusion of urokinase.
    Urano T; Kamiya T; Sakaguchi S; Takada Y; Takada A
    Thromb Res; 1985 Jul; 39(2):145-55. PubMed ID: 3161212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of arterial thrombosis successfully treated with a large dosage of urokinase--study on urokinase administration with special reference to alpha2-plasmin inhibitor (author's transl)].
    Hayashi S; Yamada K
    Rinsho Ketsueki; 1979 Apr; 20(4):400-9. PubMed ID: 156270
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal antibodies inhibitory to human plasmin. Definitive demonstration of a role for plasmin in activating the proenzyme of urokinase-type plasminogen activator.
    Sim PS; Fayle DR; Doe WF; Stephens RW
    Eur J Biochem; 1986 Aug; 158(3):537-42. PubMed ID: 2942403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolysis and thrombosis of fibrinogen-modified gold nanoparticles for detection of fibrinolytic-related proteins.
    Jian JW; Chiu WC; Chang HT; Hsu PH; Huang CC
    Anal Chim Acta; 2013 Apr; 774():67-72. PubMed ID: 23567118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.